Larimar Therapeutics, Inc. — Director's Dealing 2016

Aug 31, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ZAFGEN, INC. (ZFGN)
CIK: 0001374690
Period of Report: 2016-08-29

Reporting Person: Hughes Thomas E. (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-08-29	Common Stock	P	10000	$2.9987	Acquired	63936	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.985 to $3.00, inclusive. The reporting person undertakes to provide to Zafgen, Inc., any security holder of Zafgen, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.